EUVIMEDEUVIMED entdecken
Crossref

Opportunities for pharmacist prescriptive authority of buprenorphine following passage of the Mainstreaming Addiction Treatment (MAT) Act

Jennifer Athay Adams, Nicole L Chopski, Alex J Adams

Journal of the American Pharmacists Association · 2023

DOI: 10.1016/j.japh.2023.06.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Pharmacists Association, 2023. Verfasst von Jennifer Athay Adams und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Buprenorphine, Opiate Overdose, Opioid-Related Disorders. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In December 2022, Congress passed the Mainstreaming Addiction Treatment Act, which removed the federal legal barrier to pharmacist buprenorphine prescribing. As a result, each state can now decide whether or not to allow pharmacists to prescribe buprenorphine as an additional access point to reduce fatal opioid overdoses. At least 10 states allow pharmacists to prescribe controlled substances under collaborative practice agreements. Two states (California and Idaho) have also created pathways for independent prescribing of buprenorphine by pharmacists. Additional states should seek to enable pharmacists to prescribe buprenorphine to increase access to a proven beneficial treatment and help reduce fatal opioid overdoses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuprenorphineOpiate OverdoseOpioid-Related DisordersHumansUnited StatesPharmacistsDrug PrescriptionsIdaho

Substanzen

Buprenorphine

Zitieren

APA

Adams, J. A., Chopski, N. L., & Adams, A. J. (2023). Opportunities for pharmacist prescriptive authority of buprenorphine following passage of the Mainstreaming Addiction Treatment (MAT) Act. Journal of the American Pharmacists Association. https://doi.org/10.1016/j.japh.2023.06.001

Vancouver

Adams JA, Chopski NL, Adams AJ. Opportunities for pharmacist prescriptive authority of buprenorphine following passage of the Mainstreaming Addiction Treatment (MAT) Act. Journal of the American Pharmacists Association. 2023. doi:10.1016/j.japh.2023.06.001

BibTeX
@article{Adams2023,
  author = {Adams, Jennifer Athay and Chopski, Nicole L and Adams, Alex J},
  title = {Opportunities for pharmacist prescriptive authority of buprenorphine following passage of the Mainstreaming Addiction Treatment (MAT) Act},
  journal = {Journal of the American Pharmacists Association},
  year = {2023},
  doi = {10.1016/j.japh.2023.06.001}
}
Kostenlos starten →